Literature DB >> 16841245

Design of iron chelators: syntheses and iron (III) complexing abilities of tripodal tris-bidentate ligands.

Amaury du Moulinet d'Hardemare1, Stéphane Torelli, Guy Serratrice, Jean-Louis Pierre.   

Abstract

The interest in synthetic siderophore mimics includes therapeutic applications (iron chelation therapy), the design of more effective agents to deliver Fe to plants and the development of new chemical tools in order to study iron metabolism and iron assimilation processes in living systems. The design of ligands needs a rational approach for the understanding of the metal ion complexing abilities. The octahedral arrangement of donor atoms is the most favourable geometry, allowing the maximum possible distance between their formal or partial negative charges. Hexadentate chelators, usually of the tris-bidentate type, can accommodate the metal coordination sphere and are well-suited to obtain high pFe values. The first part of this review is dedicated to selected synthetic routes, taking into account (i) the nature of the chelating subunits, connecting groups and spacers, (ii) the water-solubility and hydrophilic/lipophilic balance, (iii) the chirality and (iv) the possibility of grafting probes or vectors. In the second part, we discuss the role of the molecular design on complexing abilities (thermodynamics and kinetics). The bidentate 8-hydroxyquinoline moiety offers an alternative to the usual coordinating hydroxamic acids, catechols and/or alpha-hydroxycarboxylic acids groups encountered in natural siderophores. The promizing results obtained with the tris-hydroxyquinoline-based ligand O-TRENSOX are summarized. O-TRENSOX exhibits a high and selective affinity for Fe(III) complexation. Its efficiency in delivering Fe to plants, iron mobilization, cell protection, and antiproliferative effects has been evidenced. Other chelators derived from O-TRENSOX (mixed catechol/8-hydroxyquinoline ligands, lipophilic ligands) are also described. Some results question the relevance of partition coefficients to foresee the activity of iron chelators. The development of probes (fluorescent, radioactive, spin labelled) based on the O-TRENSOX backbone is in progress in order to get insights in the complicated iron metabolism processes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16841245     DOI: 10.1007/s10534-005-2997-2

Source DB:  PubMed          Journal:  Biometals        ISSN: 0966-0844            Impact factor:   2.949


  6 in total

1.  Preparation of bifunctional isocyanate hydroxamate linkers: Synthesis of carbamate and urea tethered polyhydroxamic acid chelators.

Authors:  Rasika Fernando; Jonathan M Shirley; Emilio Torres; Hollie K Jacobs; Aravamudan S Gopalan
Journal:  Tetrahedron Lett       Date:  2012-11-21       Impact factor: 2.415

2.  Synthetic approaches to mixed ligand chelators on t-butylphenol-formaldehyde oligomer (PFO) platforms.

Authors:  Jennifer A Young; Sukhen Karmakar; Hollie K Jacobs; Aravamudan S Gopalan
Journal:  Tetrahedron       Date:  2012-12-02       Impact factor: 2.457

3.  Curcumin reduces the toxic effects of iron loading in rat liver epithelial cells.

Authors:  Donald J Messner; Gowsala Sivam; Kris V Kowdley
Journal:  Liver Int       Date:  2008-05-19       Impact factor: 5.828

4.  Preparation of 3-benzyloxy-2-pyridinone functional linkers: Tools for the synthesis of 3,2-hydroxypyridinone (HOPO) and HOPO/hydroxamic acid chelators.

Authors:  Sarah Gibson; Rasika Fernando; Hollie K Jacobs; Aravamudan S Gopalan
Journal:  Tetrahedron       Date:  2015-12-08       Impact factor: 2.457

5.  In-Depth Analyses of B Cell Signaling Through Tandem Mass Spectrometry of Phosphopeptides Enriched by PolyMAC.

Authors:  Anton Iliuk; Keerthi Jayasundera; Wen-Horng Wang; Rachel Schluttenhofer; Robert L Geahlen; W Andy Tao
Journal:  Int J Mass Spectrom       Date:  2015-02-01       Impact factor: 1.986

6.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.